cyrilzakka/clinical-trials huggingface dataset:
ScentAware and OCT in MCI vs HC

The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are:

* Whether the test is as effective and reliable as the standard test
* Whether there is a link between the results of the smell test and the structure of the back of the eye

Participants will:

* complete a short questionnaire
* have pictures of the inside of their eyes taken
* perform two smell tests


Eligibility Criteria:
Inclusion Criteria:

* Adults who are ≥ 50 and ≤ 80 years of age
* Fluent in English
* Able to provide written consent
* Able to complete a 2.5-3-hour clinical visit, including sitting for spectral domain optical coherence tomography (SD-OCT) imaging for 30 minutes and taking cognitive and olfactory tests for 90-120 minutes
* Cognitive Ability and Family History of Alzheimer's Disease/Mild Cognitive Impairment (AD/MCI):

  * Cohort 1: Cognitively unimpaired, no family history of MCI or AD, and MMSE ≥ 26
  * Cohort 2: Cognitively unimpaired, a positive family history of MCI or AD, and MMSE ≥ 26
  * Cohort 3: An MMSE score \> 22 and ≤ 25 and either

    * Clinically diagnosed MCI due to AD
    * A participant in a Wisconsin ADRC research registry with either clinically diagnosed MCI or self-reported MCI
* Cohorts 1 and 2: proficient in independent use of mobile smart devices

Exclusion Criteria:

* A history of significant ocular or nasal trauma that required medical/surgical intervention
* A history of intraocular surgery except cataract extraction
* A cataract extraction within 3 months prior to enrollment
* Diagnosis of visually significant intraocular disease (such as late-stage age-related macular degeneration, glaucoma, or other optic nerve conditions related to brain tumor or multiple sclerosis), drug related vision loss or retinal damage
* Optic neuritis on both eyes
* Current use of medications that may interfere with olfactory functions
* Current use of hydroxychloroquine and tamoxifen, which are known to cause retinal toxicity that may confound OCT interpretation
* A history of recurrent or chronic oto-pharyngeal-laryngeal (ORL) disease (such as chronic rhinitis, nasal polyposis, or sinus disease), head trauma, toxic exposures, upper respiratory infections at time of assessment
* A family history or diagnosis of other neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease) or conditions that, in the opinion of the Investigators, may affect cognitive or olfactory functions
* Olfactory loss due to COVID (current olfactory loss and/or temporary loss that has been regained)
Intravaginal Laser Treatment of Mild and Moderate Stress Incontinence

The aim of the study is to evaluate the effectiveness of laser therapy as a non-surgical treatment option in patients with mild and moderate stress incontinence.

The aim of the study is to evaluate the effectiveness of laser therapy as a non-surgical treatment option in patients with mild and moderate stress incontinence.

Eligibility Criteria:
Inclusion Criteria:

* Light or moderate stress incontinence
* mixed urine incontinence with predominance of the stress component
* written informed consent

Exclusion Criteria:

* Pregnancy
* patients treated radiotherapy in the small basin
* connective tissue disorders (e.g., Ehlers-Danlos syndrome, Marfan syndrome)
* patient with or after malignant disease of the uterus, ovaries, vagina and vulva
* former surgery due to stress incontinence (except for the patients who had a TVT insert with removal of the TVT)
* Descensus genitalis\> POPQ Stage 1
* former surgery due to a genital lowering with vaginal netting
Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

To determine whether the combination of ezetimibe and simvastatin improves biomarkers of atherothrombosis compared to simvastatin alone in patients with the metabolic syndrome.

1. To assess the ex vivo effects of ezetimibe/simvastatin (E/S) (Vytorin 10/40mg) and simvastatin (S) (Zocor 40mg) on platelet and inflammation biomarkers in patients with documented metabolic syndrome.
2. To compare platelet-related effects including PAR-1 receptor inhibition of E/S with those of the established anti-platelet agents including aspirin, clopidogrel, intravenous and oral glycoprotein IIb/IIIa inhibitors.
3. To determine whether the addition of ezetimibe will yield extra protection beyond lipid modulation in the reduction of inflammation and platelet activation.

Eligibility Criteria:
Inclusion Criteria:

1. Men and women greater than or equal to 21 years of age
2. Diagnosis of metabolic syndrome. We defined the presence of metabolic syndrome based on the US National Cholesterol Education Program's Adult Treatment Panel III guidelines. Specifically, metabolic syndrome will be diagnosed and documented when 3 of the following 5 characteristics will be present:

   * abdominal obesity, given as waist circumference for men \> 102 cm, and for women \> 88 cm
   * triglycerides \> 150 mg/dL
   * HDL cholesterol \< 40 mg/dL for men, and \< 50 mg/dL for women
   * blood pressure \> 130/85 mm Hg
   * fasting glucose \> 100 mg/dL

Exclusion Criteria:

1. Patients will be excluded for a history of bleeding diathesis
2. drug or alcohol abuse
3. prothrombin time greater than 1.5 times control
4. platelet count \< 100,000/mm3
5. hematocrit \< 25%
6. creatinine \> 4.0 mg/dl
7. surgery or angioplasty performed within 3 months or planned for the future
8. history of gastrointestinal or other bleeding
9. history of drug-induced disorders
10. trauma, cancer, rheumatic diseases, coronary artery disease or stroke
11. Patients participating in other investigational drug trials within one month of completion will be also excluded
12. Patients treated with intravenous platelet glycoprotein IIb/IIIa inhibitors or thienopyridines, within past 6 months
13. Patients treated with statins or aspirin within past four weeks
Recreational Futsal for Controlled Hypertension

Arterial hypertension (HT) was the leading global contributor for premature deaths in 2015. Its treatment includes medication and lifestyle changes, namely diet and regular exercise, which has shown to have an inverse relationship with arterial HT.

Recreational soccer (RS) has proven to be a non-pharmacological treatment for several chronic conditions, including arterial HT, with meaningful decreases on blood pressure (BP). Recreation futsal (RF) is expected to elicit comparable BP changes to RS considering that it imposes similar physical and physiological demands.

However, the effects of RF on BP and other cardiovascular markers have not been previously investigated in participants only with controlled arterial HT. Furthermore, acute BP changes and double product elicited by this exercise modality were never described.

Therefore, the main purpose of this study is to assess if RF is an effective coadjuvant intervention for BP control in adults with controlled arterial HT. Secondary purposes are: i) to determine the impact of RF on other cardiovascular markers; ii) to describe the acute BP changes and the double product elicited by RF; and iii) to assess the impact of 1 month of detraining on BP and other cardiovascular markers (4 months).

Statistical analysis:

The efficacy of the intervention will be assessed by comparing the differences between groups at follow-up, adjusted for the outcome baseline values, systolic blood pressure, maximum oxygen consumption and age (ANCOVA).

Intention-to-treat approach will be the main analysis. The missing data will be imputed by using multiple linear regression.

A per protocol analysis will also be performed (intervention group: attendance of at least 62.5% of the training sessions; control group: participants that did not engage in regular and supervised physical exercise or had an increase in dose or number of antihypertensive medication).

The significance level will be set at 5%.

Randomization:

Stratified by baseline systolic blood pressure and maximum oxygen consumption.

Contingency plan:

If the recruitment rate is below than expected, potential measures are to include: i) 30-35- and 60-65-year-old participants; ii) participants with pre-hypertension or uncontrolled hypertension.

Eligibility Criteria:
Inclusion Criteria:

* Medicated controlled hypertension, with habitual SBP below 140 mmHg and DBP below 90 mmHg;
* Males with 35-60 years;
* Not being engaged in regular and supervised physical exercise in the last 6 months;
* Medical clearance;
* Vaccinated against SARS-COV-2.

Exclusion Criteria:

* Cardiovascular disease (heart failure), cerebrovascular disease, advanced retinopathy or kidney failure;
* Resistant hypertension;
* History of cardiovascular event.
Stress and Sleep Study

This between-subject, longitudinal pilot study in healthy college students aims to explore the acceptability and preliminary outcomes of two novel and complementary interventions that may improve stress and sleep: transcutaneous vagus nerve stimulation (tVNS) and a mobile mindfulness intervention.


Eligibility Criteria:
Inclusion Criteria:

* Undergraduate student (ages 18-30)
* Must own a smartphone
* Must be able to read and write English

Exclusion Criteria:

* Major medical illnesses including diagnosed severe neurological illnesses (e.g., stroke, seizure history), medical conditions associated with neurological effects (e.g. heart, kidney disease), autoimmune disorders, and severe psychiatric diseases (e.g., schizophrenia)
* Pregnancy
* History of brain surgery, tumor, intracranial metal implantation, pacemakers or other implanted devices
* History of adverse reaction to electrical nerve stimulation
* Prescribed sleep medications and/or psychotropic medications
* Illicit or prescription drug abuse within the last two months (marijuana or alcohol abuse \>2 weeks out will be acceptable for inclusion)
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

This study is performed to confirm the optimal dose for THR (total hip replacement).


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion Criteria:

* Patient with risk of clinical significant bleeding
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

This 2 arm study will compare the efficacy and safety of the standard chemotherapy of the East German Study Group for Hematology and Oncology versus standard chemotherapy plus MabThera (375mg/m2 iv, once monthly for 8 cycles) in patients with indolent non-Hodgkin's and mantle cell lymphoma. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients \>=18 years of age;
* advanced, low-grade non-Hodgkin's and mantle cell lymphoma.

Exclusion Criteria:

* possibility of curative radiation therapy;
* secondary NHL;
* participation in another clinical trial eg with cytostatic chemotherapy or cytokines;
* concomitant diseases and/or restricted organ function precluding therapy according to the study protocol.
Exploratory Study of "Natural Killer" Inflammatory Lymphocytes in Waste Per-operating of Tonsillectomy

The aim of this study is to describe the frequency of the presence of cells Natural Killer (NK) expressing CD86 and HLA - DR in tonsils


Eligibility Criteria:
Inclusion Criteria:

* patient with programmed tonsillectomy as part of the care

Exclusion Criteria:

* patient opposition to use its waste of per-operating tonsillectomy for research purposes
* patient with immunosuppressive and/or corticoid treatment (\> 1 mg/kg)
Symptomatic Efficacy of Diacerein in Knee Osteoarthritis

Pain is the main symptom of osteoarthritis that motivates medical visits. Diacerhein has already demonstrated its efficacy in knee and/or hip osteoarthritis. This study aims at confirming the efficacy of diacerhein in symptomatic knee osteoarthritis using known and validated criteria and according to the recommendations and guidelines for this kind of study.


Eligibility Criteria:
Inclusion Criteria:

* Painful primary osteoarthritis (VAS ≥ 40 mm)
* Radiologically proven (Kellgren \& Lawrence grade I to III)
* Requiring the prescription of a symptomatic treatment of pain

Exclusion Criteria:

* Severe associated diseases
* Wash-out: AINS, Coxibs, Paracetamol, anti-osteoarthritic treatments, hyaluronic acid, knee tidal lavage
* Other osteoarticular disease
An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns

The purpose of the study is to compare an acellular epithelial skin substitute with autologous split-thickness skin grafts (STSGs) in deep partial-thickness burns. The objective is to evaluate skin quality and scar formation by using subjective and objective burn scar assessments in order to present valuable data for another additional option of wound coverage in deep partial-thickness burns. The investigators hypothesized that the acellular epithelial skin substitute is at least not inferior to autologous skin grafts.


Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years of age
* verified deep partial-thickness burns
* early tangential excision of burn wound (3-5 days after trauma)

Exclusion Criteria:

* Pregnancy
* ABSI-Score \>13
* Active tumor or immune-mediated disease
* Patient refusal
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.


Eligibility Criteria:
Inclusion Criteria:

* Clinically diagnosed with renal cell carcinoma confirmed by pathology, including clear renal cell carcinoma and type I papillary renal cell carcinoma, type II papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal cell carcinoma with sarcomatoid differentiation, etc

  * Have distant metastasis
  * metastatic RCC
  * Eastern Cooperative Oncology Group 0 to 1
  * No obvious abnormality was found in blood routine examination, coagulation and liver and kidney function

Exclusion Criteria:

* • Previously received systematic treatment

  * Failure to obtain baseline tumor tissue / blood samples
  * A history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation
  * A history of allergy to disease treatment drugs
  * During lactation or pregnancy
The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife

Based on the inclusion and exclusion criteria, patients with allergic rhinitis who meet the requirements are selected as trial subjects, and the efficacy is clarified in a randomized controlled design trial. We will Use the total nasal symptom score as the primary outcome index, serum chemokine, intercellular adhesion molecule-1, eosinophil cationic protein, total non-nasal symptom score, and rhinitis-related quality of life scale as secondary outcome indexes, and oral cetirizine hydrochloride tablets and nasal budesonide spray as the control group, the efficacy of the subjects in the electroacupuncture combined with microneedle knife group and the drug group will be observed respectively before treatment, after 2 weeks of treatment, after 4 weeks, 1 month follow-up after the end of treatment, and 3 months follow-up after the end of treatment. 4 weeks later, 1 month follow-up after the end of treatment and 3 months follow-up after the end of treatment.


Eligibility Criteria:
Inclusion Criteria:

1. Those with clinical and laboratory diagnosis of moderate to severe allergic rhinitis;
2. Aged ≥18 years and ≤75 years, with no restriction on gender or ethnicity;
3. Not taking drugs such as antihistamines or nasal steroids within 1 month before enrollment;
4. Those who voluntarily participated in this study and signed an informed consent form, and who were able to adhere to outpatient treatment for 4 weeks.

Exclusion Criteria:

1. Atrophic rhinitis, hypertrophic rhinitis, vasomotor rhinitis, acute and chronic sinusitis, nasal polyps, severe septal deviation, eosinophilia non-allergic rhinitis;
2. Those with other allergic diseases such as asthma, urticaria, and colds that cause nasal congestion, runny nose, and sneezing;
3. Those who have serious diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems in combination;
4. Pregnant or lactating women, psychiatric patients, patients with malignant tumors.
Impact of Regular Consumption of Grapes on Eye Health in Singapore Older Adults

Aging epidemics in Singapore are rapidly increasing and Age-related macular degeneration (AMD) prevalence is significantly associated with older age. This study aims to understand the effect of consuming freeze-dried table grape powder on AMD in an older population.

This will be carried out through a 16-week double-blind, randomized, placebo-controlled trial of parallel study design. Thirty-eight men and women (aged between 60 and 85 years old inclusive) will recruited and assigned to an intervention or placebo group. The intervention group will consume 46 g/day of a freeze-dried table grape and the control group will consume the same amount of a placebo, table grape placebo powder. Measurements of 1) macular pigment optical density (MPOD), a clinical marker for eye health, 2) carotenoids status, 3) markers of oxidative stress, 4) markers of endothelial function, 5) body size and blood pressure, and 6) dietary assessment will be assessed over the 16-week study. This study will consist of 1 screening visit and 5 study visits in 4-week intervals to the Food Science and Technology Department, Occupational Health Clinic and National University Heart Centre.

Eligibility Criteria:
Inclusion Criteria:

* Male and female participants, aged between 60 and 85 years old inclusive
* Able to give informed consent in English

Exclusion Criteria:

* Smokers
* Allergy to grapes
* Known eye diseases (macular degeneration, cataracts, retinopathy or glaucoma), blindness in at least one eye or have had eye surgery
* Abnormal kidney and liver function
* Taking eye medication and/or dietary supplements for the eyes for the past 3 months
* Taking supplements containing carotenoids (e.g. Vitamin A, lutein, zeaxanthin) for the past 3 months
* Currently on type 2 diabetic medication.
* Currently on anti-hypertensive or cholesterol-lowering; unless this prescription has been ongoing for more than 3 years prior to study participation.
* Currently on a specialized diet (e.g. vegetarian, vegan, weight loss diet, low fat diet)
* Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit.
* Significant change in weight (≥ 3 kg body weight) in the past 3 months
* Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
* Poor peripheral venous access based on past experiences with blood draw
* Participating in another clinical study
Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis

This investigation aims to investigate the frequency of pes planus and posterior tibial tendon dysfunction in patients with ankylosing spondylitis.

Posterior tibial tendon dysfunction is the most common cause of acquired pes planus deformity in healthy adults. The posterior tibial tendon stabilizes the hindfoot against valgus and eversion forces and acts as a support along the medial longitudinal arch. If the posterior tibial tendon loses its functionality, the other ligaments of the foot and the joint capsule gradually weaken as the height of the medial longitudinal arch decreases or disappears, and it develops with pes planus. The presence of pes planus and spondyloarthropathy are also risk factors for the development of posterior tibial tendon dysfunction.

100 participants aged between 20-70 years with ankylosing spondylitis were planned to be included in this investigation. Posterior tibial tendon dysfunction frequency of patients with ankylosing spondylitis will be evaluated by both clinical examination and musculoskeletal ultrasonography device. The posterior tibial tendon will be evaluated by ultrasonography in terms of tendon diameter and fluid presence in 2 different locations in the retromalleolar area.

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life (ASQoL) Scale, Functional reach test, Timed up and go test, Berg Balance Scale, Dynamic and static balance with the Sportkat device will be used as evaluation parameters. It was planned that the evaluations were made once.

Eligibility Criteria:
Inclusion Criteria:

* Participitans who apply to the rheumatology outpatient clinic between the ages of 20-70 and who have been diagnosed with ankylosing spondylitis according to the Modified Newyork criteria will be included in this study.

  1. Ankylosing Spondilitis

Exclusion Criteria:

1. Malignity
2. Previous ankle surgery history
3. Muscle disease
4. Neuropsychiatric illnesses
5. İmbalance
6. Visual problems
7. Deafness
Prevalence and Risk Factors of Helicobacter Pylori Infection in Children and Young Adults

Helicobacter pylori is a gram-negative bacterium that resides in the stomach and can cause inflammation leading to long-term effects, such as gastric ulcers, cancer, and lymphoma of the stomach mucosal linings Previous research and analysis of H. pylori prevalence in populations have examined common risk factors that increase the likelihood of acquiring the bacteria. Some of the most commonly identified risk factors across various studies in different geographic populations are larger family size, less education, lower socioeconomic status, less frequent hygiene practices, and lower sanitation with specific emphasis on sources of water and defecation.

aim of the work: Studying prevalence of Helicobacter Pylori infection and its related risk factors in children and young adults in Sohag governorate.


Eligibility Criteria:
Inclusion Criteria:

* children and young adults (between 2 to 25 years old)

Exclusion Criteria:

* children below 2 years old
* adults more than 25 years old